2024
Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, DOI: 10.1001/jamanetworkopen.2024.40591.Peer-Reviewed Original ResearchConceptsProstate-specific antigenProstate-specific antigen levelPSMA-PETRecurrent prostate cancerBiochemical recurrenceProstate cancerLong-term outcomesProstate-specific membrane antigen positron emission tomographyEvaluation of biochemical recurrenceDetection of biochemical recurrenceLife yearsConventional imagingDefinitive local therapyPSMA PET imagingProstate cancer deathDetection of metastasesRetrospective cohort studyBase case analysisIncremental life-yearsPositron emission tomographyDecision-analytic modelLocal therapyConventional imaging strategiesDelayed treatmentDisease courseNet Monetary Benefit Lines Augmented with Value-of-Information Measures to Present the Results of Economic Evaluations under Uncertainty
Yaesoubi R, Kunst N. Net Monetary Benefit Lines Augmented with Value-of-Information Measures to Present the Results of Economic Evaluations under Uncertainty. Medical Decision Making 2024, 44: 770-786. PMID: 39056310, DOI: 10.1177/0272989x241262343.Peer-Reviewed Original ResearchResults of cost-effectiveness analysesNet monetary benefitCost-effectiveness planeCost-effectiveness analysisMonetary benefitsDecision uncertaintyDecision problemEffect estimatesHypothetical decision problemResults of economic evaluationsValue-of-informationDecision makersCost-effectiveness ratioEconomic evaluation studiesCorrelated costsHigh varianceLevel of uncertaintyParameter uncertaintiesEconomic evaluationMagnitude of parametersMakersDecisionUncertaintyCostMonetaryMaking Drug Approval Decisions in the Face of Uncertainty: Cumulative Evidence versus Value of Information
Dijk S, Krijkamp E, Kunst N, Labrecque J, Gross C, Pandit A, Lu C, Visser L, Wong J, Hunink M. Making Drug Approval Decisions in the Face of Uncertainty: Cumulative Evidence versus Value of Information. Medical Decision Making 2024, 44: 512-528. PMID: 38828516, PMCID: PMC11283736, DOI: 10.1177/0272989x241255047.Peer-Reviewed Original ResearchValue-of-informationVOI approachPolicy decisionsValue-of-information analysisSuboptimal resource useEvidence accumulationVOI resultsAdministrative policy decisionsDecision making resultsDecision-making strategiesApproval decisionsPolicy approachesMeta-analysisResearch settingsResource useHealth technology assessmentCrisis responseCase studyPolicyCumulative evidenceResource allocationComplexity of decisionsResearch prioritizationDecisionHealth outcomesPD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY
Leapman M, Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Kunst N, Wang S, Ma X, Gross C, Karnes R. PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2024, 211: e971. DOI: 10.1097/01.ju.0001008792.09108.b4.10.Peer-Reviewed Original ResearchPD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING
Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. PD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING. Journal Of Urology 2024, 211: e177. DOI: 10.1097/01.ju.0001008576.33217.96.10.Peer-Reviewed Original ResearchMP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM
Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. MP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM. Journal Of Urology 2024, 211: e940. DOI: 10.1097/01.ju.0001009420.83948.eb.08.Peer-Reviewed Original ResearchPD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES
Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. PD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES. Journal Of Urology 2024, 211: e972. DOI: 10.1097/01.ju.0001008792.09108.b4.11.Peer-Reviewed Original ResearchTemporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States.
Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States. Journal Of Clinical Oncology 2024, 42: 34-34. DOI: 10.1200/jco.2024.42.4_suppl.34.Peer-Reviewed Original ResearchProportion of patientsProstate cancerPSMA-PETPET imagingProstate specific membrane antigen positron emission tomographyDiagnosis of prostate cancerProstate cancer visualizationPSMA PET imagingPSMA-targeted agentsPositron emission tomography imagingCochran-Armitage testDynamic cohort studyPositron emission tomographyCommercial insurance beneficiariesEmission tomography imagingChi-square testCancer visualizationCholine tracersCohort studyProstateTreatment decisionsBlue Cross Blue Shield AxisCochran-ArmitageEmission tomographyInsurance beneficiaries
2023
A Guide to an Iterative Approach to Model-Based Decision Making in Health and Medicine: An Iterative Decision-Making Framework
Kunst N, Burger E, Coupé V, Kuntz K, Aas E. A Guide to an Iterative Approach to Model-Based Decision Making in Health and Medicine: An Iterative Decision-Making Framework. PharmacoEconomics 2023, 42: 363-371. PMID: 38157129, DOI: 10.1007/s40273-023-01341-z.Peer-Reviewed Original ResearchModel-based decision analysisDecision-making frameworkModel-based economic evaluationsDecision analysisDecision makersEconomic evaluationOptimal resource allocationHealth care decisionsResource allocationDecision optionsDecision-making processDecisionsCoherent frameworkMakersModel-based decisionInformation analysisDecision makingComment on: “Adding Value to CHEERS: New Reporting Standards for Value of Information Analyses”
Kunst N, Siu A, Drummond M, Grimm S, Grutters J, Husereau D, Koffijberg H, Rothery C, Wilson E, Heath A. Comment on: “Adding Value to CHEERS: New Reporting Standards for Value of Information Analyses”. Applied Health Economics And Health Policy 2023, 22: 265-267. PMID: 38141116, DOI: 10.1007/s40258-023-00856-y.Peer-Reviewed Original ResearchThe Expected Value of Perfect or Partial Perfect Information
Jackson C, Jalal H, Heath A, Kunst N, Thom H, Welton N, Tuffaha H, Wilson E. The Expected Value of Perfect or Partial Perfect Information. 2023, 47-91. DOI: 10.1201/9781003156109-3.Peer-Reviewed Original ResearchThe Expected Value of Sample Information
Heath A, Strong M, Jackson C, Kunst N, Welton N, Jalal H, Wilson E. The Expected Value of Sample Information. 2023, 92-168. DOI: 10.1201/9781003156109-4.Peer-Reviewed Original ResearchValue of Information: Success Stories
Kunst N, Wilson E, Tuffaha H, Jackson C, Welton N, Jalal H, Alarid-Escudero F. Value of Information: Success Stories. 2023, 193-206. DOI: 10.1201/9781003156109-6.Peer-Reviewed Original ResearchReporting Economic Evaluations with Value of Information Analyses Using the CHEERS Value of Information (CHEERS-VOI) Reporting Guideline
Kunst N, Siu A, Drummond M, Grimm S, Grutters J, Husereau D, Koffijberg H, Rothery C, Wilson E, Heath A. Reporting Economic Evaluations with Value of Information Analyses Using the CHEERS Value of Information (CHEERS-VOI) Reporting Guideline. Medical Decision Making 2023, 44: 127-128. PMID: 38097383, DOI: 10.1177/0272989x231214791.Peer-Reviewed Original Research
2022
Treatment patterns and medical costs of metastatic breast cancer care in the United States.
Chehayeb R, Hood A, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment patterns and medical costs of metastatic breast cancer care in the United States. Journal Of Clinical Oncology 2022, 40: e18834-e18834. DOI: 10.1200/jco.2022.40.16_suppl.e18834.Peer-Reviewed Original ResearchMetastatic breast cancerTreatment patternsTreatment costsDiagnosis of MBCSocietal perspectiveHormone receptor statusBreast cancer careDays of diagnosisDe-identified databaseAverage wholesale priceElectronic health recordsMBC patientsMBC diagnosisReceptor statusCancer careInvasive cancerTriple NegativeClinical trialsReceptor subtypesPatient levelBreast cancerHuman epidermal growth factorPayer perspectiveDrug costsEpidermal growth factorMethods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison
Wolff H, Qendri V, Kunst N, Alarid-Escudero F, Coupé V. Methods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison. Medical Decision Making 2022, 42: 956-968. PMID: 35587181, PMCID: PMC9452448, DOI: 10.1177/0272989x221100112.Peer-Reviewed Original ResearchConceptsCost-effectiveness acceptability curvesCost-effectiveness acceptability frontierCost-effectiveness analysisImpact of uncertaintyAcceptability curvesDecision analytic modelWrong decisionsCost-effectiveness comparisonBenefit curvePolicy makersHeat mapDecision makersPotential lossIntegration of methodsDecisionsIntegration of informationDecision problemMakersOverview of methodsUncertaintyHealth policyType of informationCourse of actionRelevant informationUse toolEmerging Therapies for COVID-19: The Value of Information From More Clinical Trials
Dijk SW, Krijkamp EM, Kunst N, Gross CP, Wong JB, Hunink MGM. Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials. Value In Health 2022, 25: 1268-1280. PMID: 35490085, PMCID: PMC9045876, DOI: 10.1016/j.jval.2022.03.016.Peer-Reviewed Original ResearchConceptsCohort state-transition modelUS healthcare perspectiveValue of informationFace of uncertaintyQALY willingnessPolicy makersLifetime horizonHealthcare perspectiveState transition modelInformation analysisImmediate approvalModel outcomesImplementation decisionsOptimal momentWillingnessPolicyMakersMost valueCOVID-19DecisionsCostHorizonFurther researchAdditional evidenceUncertaintyCost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia
Goshua G, Sinha P, Kunst N, Pischel L, Lee AI, Cuker A. Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia. American Journal Of Hematology 2022, 98: 122-130. PMID: 35147241, PMCID: PMC9365880, DOI: 10.1002/ajh.26497.Peer-Reviewed Original ResearchConceptsThrombopoietin receptor agonistsChronic immune thrombocytopeniaSecond-line therapyImmune thrombocytopeniaEarly useCurrent practice trendsProbabilistic sensitivity analysesCost-effective treatmentFirst cost-effectiveness analysisCost-effectiveness analysisU.S. health systemLack of evidenceEarly splenectomyHematology (ASH) guidelinesReceptor agonistCurrent guidelinesSplenectomyClinical practicePractice trendsTherapyHealth systemCost-effective strategyRituximabThrombocytopeniaAmerican SocietyPopulation-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research
Kunst N, Stout N, O’Brien G, Christensen K, McMahon P, Wu A, Diller L, Yeh J. Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research. Journal Of The National Cancer Institute 2022, 114: 722-731. PMID: 35043946, PMCID: PMC9086756, DOI: 10.1093/jnci/djac013.Peer-Reviewed Original ResearchConceptsUsual careClinical benefitTP53 variantsIncremental cost-effectiveness ratioPathogenic TP53 variantsCancer-related deathGermline TP53 variantsUS birth cohortPotential health outcomesCost-effectiveness ratioIdentification of childrenTumor surveillanceClinical studiesRhabdomyosarcoma casesPediatric cancerEarly cancer detectionRoutine surveillanceBirth cohortHealth outcomesAge 20Newborn screeningMalignancy detectionFurther researchCareTP53
2021
Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
Yang SC, Kunst N, Gross CP, Wang JD, Su WC, Wang SY. Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer. Frontiers In Oncology 2021, 11: 760686. PMID: 34956882, PMCID: PMC8695441, DOI: 10.3389/fonc.2021.760686.Peer-Reviewed Original ResearchNon-small cell lung cancerIncremental cost-effectiveness ratioMetastatic non-small cell lung cancerCell lung cancerHealth care sector perspectivePD-L1Lung cancerAdvanced non-small cell lung cancerPD-L1 expression levelsCycles of chemotherapyProgression-free survivalFirst-line treatmentCost-effectiveness ratioExpression levelsCheckMate 227Overall survivalSubgroup analysisLifetime horizonOutcome dataChemotherapyPatientsIpilimumabNivolumabQALYSector perspective